Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine alternating with intermediate-dose cytarabine consolidation in older adults with newly diagnosed AML
ChiCTR2200061598Phase 3Not yet recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, azacitidine and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoints: Overall survival and Leukemia-free survival. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
venetoclaxazacitidinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200061598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061598.